RU2351337C1 - Способ уменьшения, стабилизации и предупреждения разрыва богатой липидами бляшки - Google Patents

Способ уменьшения, стабилизации и предупреждения разрыва богатой липидами бляшки Download PDF

Info

Publication number
RU2351337C1
RU2351337C1 RU2007125976/15A RU2007125976A RU2351337C1 RU 2351337 C1 RU2351337 C1 RU 2351337C1 RU 2007125976/15 A RU2007125976/15 A RU 2007125976/15A RU 2007125976 A RU2007125976 A RU 2007125976A RU 2351337 C1 RU2351337 C1 RU 2351337C1
Authority
RU
Russia
Prior art keywords
pitavastatin
pharmaceutically acceptable
hydrate
acceptable salt
lipid
Prior art date
Application number
RU2007125976/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2007125976A (ru
Inventor
Хидеюки КОБАЯСИ (JP)
Хидеюки Кобаяси
Ясунобу ЙОСИНАКА (JP)
Ясунобу ЙОСИНАКА
Кимиюки СИБУЯ (JP)
Кимиюки Сибуя
Original Assignee
Кова Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кова Ко., Лтд. filed Critical Кова Ко., Лтд.
Publication of RU2007125976A publication Critical patent/RU2007125976A/ru
Application granted granted Critical
Publication of RU2351337C1 publication Critical patent/RU2351337C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2007125976/15A 2004-12-10 2005-12-09 Способ уменьшения, стабилизации и предупреждения разрыва богатой липидами бляшки RU2351337C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63453204P 2004-12-10 2004-12-10
US60/634,532 2004-12-10

Publications (2)

Publication Number Publication Date
RU2007125976A RU2007125976A (ru) 2009-01-20
RU2351337C1 true RU2351337C1 (ru) 2009-04-10

Family

ID=36587943

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007125976/15A RU2351337C1 (ru) 2004-12-10 2005-12-09 Способ уменьшения, стабилизации и предупреждения разрыва богатой липидами бляшки

Country Status (11)

Country Link
US (2) US20090275595A1 (enExample)
EP (1) EP1827440A4 (enExample)
JP (1) JP2008522955A (enExample)
KR (1) KR100895031B1 (enExample)
CN (1) CN101068548B (enExample)
AU (1) AU2005314810B2 (enExample)
CA (1) CA2590224C (enExample)
NZ (1) NZ554924A (enExample)
RU (1) RU2351337C1 (enExample)
TW (1) TW200619204A (enExample)
WO (1) WO2006064889A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100438872C (zh) * 2003-08-29 2008-12-03 兴和株式会社 2-[4-[2-(苯并咪唑-2-基-硫代)乙基]哌嗪-1-基]-n-[2,4-二(甲基硫代)-6-甲基-3-吡啶基]乙酰胺的制药用途
US8048083B2 (en) * 2004-11-05 2011-11-01 Dfine, Inc. Bone treatment systems and methods
WO2011081118A1 (ja) * 2009-12-29 2011-07-07 興和株式会社 経口投与用医薬組成物
JPWO2011081117A1 (ja) * 2009-12-29 2013-05-09 興和株式会社 経口投与用固形医薬組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124309A (en) * 1995-11-02 2000-09-26 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration
RU2000101310A (ru) * 1997-06-16 2001-10-27 Байер Акциенгезелльшафт Способ получения лекарственных средств, содержащих ингибиторы гидроксиметилглютарил-соа-редуктазы
RU2198682C2 (ru) * 1995-06-20 2003-02-20 Такеда Кемикал Индастриз Лтд. Фармацевтическая композиция
RU2207341C2 (ru) * 1997-05-26 2003-06-27 Кова Компани, Лтд. Новые циклические соединения диамина, содержащие их лекарственные средства и способы лечения
RU2235483C2 (ru) * 1998-11-25 2004-09-10 Нутри Фарма Аса Композиция, фармацевтический препарат и способ для профилактики и/или лечения и/или ослабления сердечно-сосудистых заболеваний

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
US6969711B2 (en) * 1997-05-26 2005-11-29 Kowa Company, Ltd. Cyclic diamine compounds and medicine containing the same
WO2001022962A1 (en) * 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
IL153633A0 (en) * 2000-07-13 2003-07-06 Takeda Chemical Insustries Ltd Lipid-rich plaque inhibitors
HUP0301728A3 (en) * 2000-09-01 2004-05-28 Sankyo Co Hmg-coa reductase inhibiting pharmaceutical compositions and their use
US20060165605A1 (en) * 2001-12-28 2006-07-27 Ye-Mon Chen Process to regenerate fcc spent catalyst
MY140618A (en) * 2003-02-28 2009-12-31 Kowa Co Method for preparing acid addition salts of polyacidic basic compounds
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2198682C2 (ru) * 1995-06-20 2003-02-20 Такеда Кемикал Индастриз Лтд. Фармацевтическая композиция
US6124309A (en) * 1995-11-02 2000-09-26 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration
RU2207341C2 (ru) * 1997-05-26 2003-06-27 Кова Компани, Лтд. Новые циклические соединения диамина, содержащие их лекарственные средства и способы лечения
RU2000101310A (ru) * 1997-06-16 2001-10-27 Байер Акциенгезелльшафт Способ получения лекарственных средств, содержащих ингибиторы гидроксиметилглютарил-соа-редуктазы
RU2235483C2 (ru) * 1998-11-25 2004-09-10 Нутри Фарма Аса Композиция, фармацевтический препарат и способ для профилактики и/или лечения и/или ослабления сердечно-сосудистых заболеваний

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
реферат базы данных PubMed: Llaverias G. et al. Avasimibeand atorvastatin synergistically reduce cholesteryl ester contene in THP-1 macrophages. Eur. J.Pharmacol. 2002 Sep 6; 451(1):11-7 [on line} PMID: 12223223 [найдено 12.09.2008]. *

Also Published As

Publication number Publication date
CN101068548B (zh) 2010-12-08
US20090275595A1 (en) 2009-11-05
EP1827440A4 (en) 2010-12-08
AU2005314810B2 (en) 2010-08-26
HK1111356A1 (en) 2008-08-08
TW200619204A (en) 2006-06-16
US20110207742A1 (en) 2011-08-25
CA2590224C (en) 2011-12-20
RU2007125976A (ru) 2009-01-20
KR100895031B1 (ko) 2009-04-24
NZ554924A (en) 2010-09-30
CN101068548A (zh) 2007-11-07
KR20070085508A (ko) 2007-08-27
AU2005314810A1 (en) 2006-06-22
EP1827440A1 (en) 2007-09-05
JP2008522955A (ja) 2008-07-03
WO2006064889A1 (en) 2006-06-22
CA2590224A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
US10449154B2 (en) Treatment of NASH with Gemcabene
EP1919466B9 (en) Formulations for treatment of lipoprotein abnormalities comprising a statin and a methylnicotinamide derivative
US20150272944A1 (en) Novel triglyceride reducing agent
CN100438872C (zh) 2-[4-[2-(苯并咪唑-2-基-硫代)乙基]哌嗪-1-基]-n-[2,4-二(甲基硫代)-6-甲基-3-吡啶基]乙酰胺的制药用途
US20110207742A1 (en) Method for reduction, stabilization and prevention of rupture of lipid rich plaque
KR20110042108A (ko) 새로운 메틸렌디옥시 페놀 화합물 및 질병 치료에서 이들의 사용
KR20240040767A (ko) His 저감반응자의 치료
WO2007058335A1 (en) Use of tak-475 together with ezetimibe for treating hyperlipidemia
HK1111356B (en) Method for reduction, stabilization and prevention of rupture of lipid rich plaque
JPWO2019216313A1 (ja) 心血管疾患に有用な医薬
WO1994020096A1 (en) Method of employing carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
WO2006011495A1 (ja) 高コレステロール血症及び／又は高トリグリセリド血症治療剤
HK1111632B (en) Novel triglyceride reducing agent

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20121210